Paper32192573
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL and 10 others. Lancet Oncol, 2020. Cited by 281 papers, by iCite.
Cite this record
ConductScience Library. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Papers, record 32192573. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32192573
- Disease
- melanoma589 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
- PubMed
- Publication types
- Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Connected records7
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Diseases7
- melanomaOne of its trials lists the paper589 drugs, 1,589 trials
- non-Hodgkin lymphomaOne of its trials lists the paper492 drugs, 1,052 trials
- Hodgkins lymphomaOne of its trials lists the paper201 drugs, 425 trials
- neuroblastomaOne of its trials lists the paper173 drugs, 298 trials
- osteosarcomaOne of its trials lists the paper141 drugs, 172 trials
- Ewing sarcomaOne of its trials lists the paper130 drugs, 149 trials
- rhabdomyosarcomaOne of its trials lists the paper95 drugs, 102 trials
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Immunological | Major topic |
| Hodgkin Disease | Major topic |
| Lymphoma, Non-Hodgkin | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Neoplasms | Major topic |
| Nivolumab | Major topic |
| Adolescent | |
| Adult | |
| Child | |
| Child, Preschool | |
| Female | |
| Humans | |
| Infant | |
| Male | |
| Response Evaluation Criteria in Solid Tumors | |
| Young Adult |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA015083 | NCI NIH HHS | United States | P30CA015083 | PubMed and NIH | NIH RePORTER |
| UM1 CA228823 | NCI NIH HHS | United States | UM1CA228823 | PubMed and NIH | NIH RePORTER |
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors | Results | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 32192574 | Nivolumab in paediatric cancer: children are not little adults. | https://conductscience.org/library/papers/32192574 |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 2 | 29606586 | Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/29606586 | PubMed |
| 3 | 27451390 | Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27451390 | PubMed |
| 4 | 28408462 | Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. | Blood | 2017 | https://conductscience.org/library/papers/28408462 | PubMed |
| 5 | 27001570 | Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27001570 | PubMed |
| 6 | 25327979 | The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. | Pediatr Blood Cancer | 2015 | https://conductscience.org/library/papers/25327979 | PubMed |
| 7 | 28787259 | Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28787259 | PubMed |
| 8 | 29466156 | Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29466156 | PubMed |
| 9 | 24853691 | Declining childhood and adolescent cancer mortality. | Cancer | 2014 | https://conductscience.org/library/papers/24853691 | PubMed |
| 10 | 27998223 | Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27998223 | PubMed |
| 11 | 30160041 | Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. | Pediatr Blood Cancer | 2018 | https://conductscience.org/library/papers/30160041 | PubMed |
| 12 | 19171710 | Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19171710 | PubMed |
| 13 | 18276034 | A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation. | Comput Methods Programs Biomed | 2008 | https://conductscience.org/library/papers/18276034 | PubMed |
| 14 | 28490569 | Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. | Blood | 2017 | https://conductscience.org/library/papers/28490569 | PubMed |
| 15 | 26317305 | Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. | Appl Immunohistochem Mol Morphol | 2015 | https://conductscience.org/library/papers/26317305 | PubMed |
| 16 | 2702835 | Optimal two-stage designs for phase II clinical trials. | Control Clin Trials | 1989 | https://conductscience.org/library/papers/2702835 | PubMed |
| 17 | 25319501 | T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. | Lancet | 2015 | https://conductscience.org/library/papers/25319501 | PubMed |
| 18 | 22658127 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22658127 | PubMed |
| 19 | 28019091 | Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. | CPT Pharmacometrics Syst Pharmacol | 2017 | https://conductscience.org/library/papers/28019091 | PubMed |
| 20 | 27928714 | Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. | Invest New Drugs | 2017 | https://conductscience.org/library/papers/27928714 | PubMed |
Cited by221
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 281 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42964569 | Artificial intelligence-enabled nursing surveillance for pediatric cancer immunotherapy: integrating biomarkers, patient-reported outcomes, and long-term toxicity management. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42964569 | PubMed |
| 42952771 | Hypoxic conditioning of neuroblastoma cells promotes CD8+ T-cell dysfunction through the HIF-1α/PD-L1 axis. | Front Pediatr | 2026 | https://conductscience.org/library/papers/42952771 | PubMed |
| 42920922 | Biomarker-guided immunotherapy in osteosarcoma: from immune microenvironment profiling to patient stratification and combination strategies. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42920922 | PubMed |
| 42776062 | The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42776062 | PubMed |
| 42666611 | Treatment strategies for relapsed/refractory hemophagocytic lymphohistiocytosis in pediatric patients. | Ther Adv Hematol | 2026 | https://conductscience.org/library/papers/42666611 | PubMed |
| 42618937 | Recurrent Mandibular Ewing sarcoma in an 11-year-old boy: a rare pediatric case and review of the literature. | J Med Case Rep | 2026 | https://conductscience.org/library/papers/42618937 | PubMed |
| 42613365 | Paediatric therapeutic development workshop on osteosarcoma. | Br J Cancer | 2026 | https://conductscience.org/library/papers/42613365 | PubMed |
| 42547980 | Translational perspectives on immunotherapy targets, germline syndromes, and novel fusions. | Oncologist | 2026 | https://conductscience.org/library/papers/42547980 | PubMed |
| 42496364 | Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non-Clinical Evidence, and Regulatory Science. | J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42496364 | PubMed |
| 42441182 | Endocrine dysfunction induced by anti-PD-1 antibody and tyrosine kinase inhibitor in a pediatric patient with renal cell carcinoma. | Clin Pediatr Endocrinol | 2026 | https://conductscience.org/library/papers/42441182 | PubMed |
| 42292421 | Metabolic-immune crosstalk in osteosarcoma: mechanisms and therapeutic opportunities. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292421 | PubMed |
| 42288687 | Paediatric Therapeutic Development Workshop on rhabdomyosarcoma. | Br J Cancer | 2026 | https://conductscience.org/library/papers/42288687 | PubMed |
| 42268572 | Pediatric Melanoma: Emerging Therapies and Ongoing Clinical Trials. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/42268572 | PubMed |
| 42237783 | Immune checkpoint therapy in pediatric and adolescent lymphomas. | Haematologica | 2026 | https://conductscience.org/library/papers/42237783 | PubMed |
| 42222420 | Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors. | Front Oncol | 2026 | https://conductscience.org/library/papers/42222420 | PubMed |
| 42212138 | Dynamic changes in peripheral blood lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in metastatic osteosarcoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42212138 | PubMed |
| 42179886 | Immunotherapy and postoperative bone defect repair strategies based on osteosarcoma tumor microenvironment characteristics: balancing antitumor effects and promotion of bone regeneration. | Regen Biomater | 2026 | https://conductscience.org/library/papers/42179886 | PubMed |
| 42171699 | The role of immunotherapy in the treatment of neuroblastoma. | Surg Today | 2026 | https://conductscience.org/library/papers/42171699 | PubMed |
| 42142195 | Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? | J Neurooncol | 2026 | https://conductscience.org/library/papers/42142195 | PubMed |
| 42091739 | New biological insights into osteosarcoma-lessons from single cell sequencing studies. | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42091739 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| LILRB3 | 11025 | PubTator's text mining | https://conductscience.org/library/genes/11025 | NCBI Gene |
| NOS1 | 4842 | PubTator's text mining | https://conductscience.org/library/genes/4842 | NCBI Gene |
| NOS3 | 4846 | PubTator's text mining | https://conductscience.org/library/genes/4846 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| IPILIMUMAB | CHEMBL1789844 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1789844 | ChEMBL |
| REGORAFENIB | CHEMBL1946170 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1946170 | ChEMBL |
| NIVOLUMAB | CHEMBL2108738 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2108738 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32192573
GET https://conductscience.org/api/papers/v1/32192573/references?page=2